Autosomal Dominant Polycystic Kidney Disease Clinical Trial
Official title:
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose and an Open-Label Fixed-Dose Study in Patients With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RGLS8429
Primary Objectives - To assess the safety and tolerability of RGLS8429 - To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives - To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) - To characterize the pharmacokinetic (PK) properties of RGLS8429 - To assess the impact of RGLS8429 on renal function
Status | Recruiting |
Enrollment | 70 |
Est. completion date | June 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Key Inclusion Criteria: 1. Male or female ADPKD patients, 18 to 70 years old 2. Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon either the MRI obtained during screening, or a prior MRI obtained within 5 years of screening with documented Mayo classification) 3. eGFR between 30 to 90 mL/min/1.73 m2 4. Body mass index (BMI) 18 to 35 kg/m2 5. Must understand and consent to the study procedures explained in the ICF and be willing and able to comply with the protocol Key Exclusion Criteria: 1. Administration of tolvaptan in the 28 days before randomization 2. Subject is mentally incapacitated or has significant emotional problems 3. Any medical condition or social circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements; or may pose a risk to the subject's safety 4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening 5. Only one kidney or kidney transplant recipient 6. Participation in another clinical trial and/or exposure to any investigational drug or approved therapy for investigational use within 28 days or 5 half-lives of the investigational drug's dosing, whichever is longer, prior to dosing. The 28-day or 5-half-life windows will be calculated from the date of the last dosing in the previous study to Day 1 of the current study. |
Country | Name | City | State |
---|---|---|---|
United States | Southeastern Clinical Research Institute, LLC | Augusta | Georgia |
United States | University of Maryland School of Medicine, Nephrology | Baltimore | Maryland |
United States | Northeast Clinical Research Center | Bethlehem | Pennsylvania |
United States | Amicis Research Center | Beverly Hills | California |
United States | CARE Institute | Boise | Idaho |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | Research by Design, LLC | Chicago | Illinois |
United States | University of Chicago | Chicago | Illinois |
United States | CARE Institute | Chubbuck | Idaho |
United States | Horizon Research Group, LLC | Coral Gables | Florida |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | National Institute of Clinical Research, Inc. | Garden Grove | California |
United States | Amicis Research Center | Granada Hills | California |
United States | The Idaho Kidney Institute | Idaho Falls | Idaho |
United States | University of Iowa | Iowa City | Iowa |
United States | Mayo Clinic - Florida | Jacksonville | Florida |
United States | University of Kansas Medical Center Jared Grantham Kidney Institute | Kansas City | Kansas |
United States | California Institute of Renal Research | La Mesa | California |
United States | Nevada Kidney Disease and Hypertension Centers | Las Vegas | Nevada |
United States | Academic Medical Research Institute | Los Angeles | California |
United States | Centricity Research Phoenix Multispecialty | Mesa | Arizona |
United States | Yale Nephrology Outpatient Clinic | New Haven | Connecticut |
United States | Elixia | Orlando | Florida |
United States | Mayo Clinic - Rochester | Rochester | Minnesota |
United States | St. Clair Nephrology Research | Roseville | Michigan |
United States | Valiance Clinical Research | S. Gate | California |
United States | Swedish Center for Comprehensive Care | Seattle | Washington |
United States | Witchita Nephrology Group, PA | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Regulus Therapeutics Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of RGLS4829: Incidence of AEs | Incidence of adverse events over time | Baseline to Day 113 | |
Primary | Impact of RGLS8429 on ADPKD biomarkers | Change from baseline in PC1, PC2, NGAL, and KIM-1 urine biomarkers | Baseline to Day 113 | |
Secondary | Impact of RGLS8429 on height-adjusted total kidney volume (htTKV) | Change from baseline in htTKV | Baseline to Day 113 | |
Secondary | Pharmacokinetic properties of RGLS8429: Cmax | Maximum observed concentration (Cmax) of RGLS8429 | Baseline to Day 113 | |
Secondary | Pharmacokinetic properties of RGLS8429: Tmax | Time to maximum observed concentration (Tmax) of RGLS8429 | Baseline to Day 113 | |
Secondary | Pharmacokinetic properties of RGLS8429: t½ | Half-life of RGLS8429 (t½) | Baseline to Day 113 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02933268 -
High Water Intake in Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00759369 -
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
Completed |
NCT00598377 -
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT01039987 -
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
|
N/A | |
Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
Recruiting |
NCT05193981 -
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
|
||
Completed |
NCT03487913 -
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT06435858 -
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT05190744 -
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
|
Phase 2 | |
Recruiting |
NCT04344769 -
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
||
Active, not recruiting |
NCT02848521 -
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
|
||
Completed |
NCT01451827 -
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
Completed |
NCT01210560 -
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
|
Phase 2 | |
Completed |
NCT01336972 -
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
Completed |
NCT02134899 -
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
|
Phase 3 | |
Active, not recruiting |
NCT02729662 -
Efficacy of Tolvaptan on ADPKD Patients
|
N/A | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05288998 -
Intrarenal Microvasculature in ADPKD
|
||
Recruiting |
NCT04939935 -
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
|
Phase 3 | |
Withdrawn |
NCT01988038 -
Repository Study of Autosomal Dominant Polycystic Kidney Disease
|
N/A |